Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Horais, K.
Right arrow Articles by Yaksh, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horais, K.
Right arrow Articles by Yaksh, T. L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences 71, 263-275 (2003)
Copyright © 2003 by the Society of Toxicology


SAFETY EVALUATION

Effects of Chronic Intrathecal Infusion of a {partial} Opioid Agonist in Dogs

Kjersti Horais*, Victor Hruby{dagger}, Steven Rossi*, Dasa Cizkova*, Carol Meschter{ddagger}, Robert Dorr§ and Tony L. Yaksh*,1

* Department of Anesthesiology, University of California, San Diego, San Diego, California 92103; {dagger} College of Science, Department of Chemistry, University of Arizona, P.O. Box 210041, Tucson, Arizona 85721-0041; {ddagger} Comparative Biosciences, Inc., 2672 Bayshore Parkway, Suite 515, Mountain View, California 94043; and § University of Arizona Cancer Center, University of Arizona, P.O. Box 245024, Tucson, Arizona 85724

To define the effects of chronic spinal exposure to a highly selective {partial} opioid agonist c[DPen2,DPen5]enkephalin (DPDPE), adult beagles were prepared with chronic lumbar intrathecal catheters. Groups of dogs received intrathecal infusions (100 µl/h) of saline (vehicle), DPDPE 3 mg/ml or 6 mg/ml for 28 days. Over the 28-day period, saline or 3 mg/ml showed minimal changes in neurological function, whereas in the 6 mg/ml animals, prominent hind limb dysfunction evolved over the 28-day interval. Histopathology in control animals displayed a modest pericatheter reaction considered normal for this model. Dogs receiving DPDPE (three of four at 6 mg/ml and one of four at 3 mg/ml) but not saline (zero of four) developed large inflammatory masses (granulomas) in the intrathecal space located proximal to the catheter tip. In these masses, severe chronic inflammatory changes in combination with necrosis and fibrosis was detected. Occasional focal destruction of neuropil was detected also in the adjacent spinal cord parenchyma. These masses contained extensive accumulation of mouse antihuman macrophages (MAC)-positive inflammatory cells expressing tumor necrosis factor-{alpha} (TNF-{alpha}), revealing infiltration of macrophages, granulocytes, and monocytes. In separate animals, prepared with dual intrathecal catheters, lumbar CSF was sampled at specified time points following intrathecal bolus (3 mg/ml) and 24 h DPDPE infusion (3 mg/ml and 6 mg/ml). Steady-state cerebrospinal fluid (CSF) DPDPE levels were 18.6 ± 1.0 and 22.6 ± 4.0 µg/ml for 3 mg/ml and 6 mg/ml infusions respectively. These results indicate that this {partial} opioid agonist DPDPE produces a concentration and time-dependent formation of an intrathecal inflammatory mass.

Key Words: DPDPE; {partial} opioid agonist; dog; intrathecal; granuloma.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
JCOHome page
J.M. Saroyan, W.S. Schechter, M.E. Tresgallo, and L. Granowetter
Role of Intraspinal Analgesia in Terminal Pediatric Malignancy
J. Clin. Oncol., February 20, 2005; 23(6): 1318 - 1321.
[Full Text] [PDF]


Home page
Toxicol SciHome page
T. L. Yaksh, K. A. Horais, N. Tozier, M. Rathbun, P. Richter, S. Rossi, M. Grafe, C. Tong, C. Meschter, J. M. Cline, et al.
Intrathecal Ketorolac in Dogs and Rats
Toxicol. Sci., August 1, 2004; 80(2): 322 - 334.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.